Holger Reithinger
Member
Curtis
Germany
Biography
Dr. Holger Reithinger is Member of the Supervisory Board of Curetis BV. He is a General Partner and Head of the Munich Office of Forbion Capital Partners (since April 2010). He holds a PhD in Biochemistry, which he obtained under the supervision of Prof. Dr. Arne Skerra (founder of Forbion's portfolio company Pieris AG); all in the department of Prof. Dr. Hartmut Michel (Nobel Laureate 1988) at the Max-Planck-Institute of Biophysics. As an undergraduate, Dr. Reithinger studied Molecular Biology/Microbial Biology and Biochemistry at the Universities of Heidelberg and Munich. After his studies, Dr. Reithinger gained operational experience as a product development manager at Biometra/ Whatman Plc (now part of GE Healthcare). He started his career in Venture Capital in 1997 as an Investment Manager at Technologieholding VC GmbH which at that time was one of the leading German Venture Capital firm. Technologieholding was acquired by the 3i Group in early 2000, where Dr. Reithinger became a Director at its Germany's healthcare practice. Following this assignment he became Principal and later Partner at Global Life Science Ventures, a well-established life sciences-focused partnership with offices in Switzerland and Germany. He is Member of the Nominating and Audit Committees of the Company.
Research Interest
Pharmaceutics & Biopharmaceutics Drug Targeting & Drug Development Pharmaceutical Research Pharmaceutical Materials Pharmaceutical Formulations Pharmaceutical Biotechnology Pharmaceutical Nanotechnology Pharmaceutical Technology Pharmaceutical Manufacturing Pharmaceutical Engineering Drug Delivery Technologies Medical Devices Drug Regulatory Affairs Pharmaceutical Management
